Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 182

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 2
Chunk 182
---
 both for us and potential licensing partners.
We believe this structure, combined with the professional networks of our leadership team members, allows us to opportunistically build
a continuous pipeline of promising product innovations through our existing and potential future relationships with research institutions.
Our goal is to optimize value creation for each of our product candidates, and we intend to continuously assess the best pathway for
each as it progresses through the preclinical and clinical development process—including through internal advancement, partnerships
with established companies and spin-outs or initial public offerings, (“IPOs”)—in order to benefit patients through
the commercialization of these products. Our current active assets are licensed from Brown University and Rhode Island Hospital. Our
scientific co-founders and members of our Board of Directors (“Board”), Dr. Jack A. Elias and Dr. Jonathan Kurtis, are both
affiliated with Brown University and with Rhode Island Hospital. Our strategy is to accelerate the flow of the academic discoveries and
the required clinical development required for these product candidates and advance them commercially. The number of potential opportunities
at research universities and medical centers is large, but only a small fraction of these opportunities is currently tapped in the market.
The gap remains wide and we believe this presents an attractive opportunity for us to become an industry leader by addressing a need
to accelerate the advancement of therapeutics that can address significant unmet medical needs. The core elements that we believe differentiate
our business model include:

    ●
    Harnessing
    inventions and technologies from research universities and medical centers. We are experienced at identifying and sourcing breakthrough
    discoveries at academic and research institutions, including our current partnerships with Brown University and Rhode Island Hospital.

    ●
    Developing
    new drug therapies through an operationally efficient, evidence-based and milestone- driven approach. Once we select an asset for
    development, we pursue what we believe are appropriate development strategies that we aim to execute efficiently by leveraging contract
    research and contract manufacturing organizations, or contract research organizations (“CROs”) and contract manufacturing
    organizations (“CMOs”), and other drug development experts and consultants.

136

    ●
    Building
    a diverse portfolio of product candidates. We are evidence-based and program agnostic, meaning that our resources are driven strictly
    by program progress and milestone achievements. Our approach is to develop multiple diverse programs in parallel which mitigates
    business risk.

    ●
    Providing
    attractive economic upside to our partners at research universities and medical centers. We have a structure wherein our parent